1. Home
  2. ELVN vs PRSU Comparison

ELVN vs PRSU Comparison

Compare ELVN & PRSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • PRSU
  • Stock Information
  • Founded
  • ELVN 2016
  • PRSU 1926
  • Country
  • ELVN United States
  • PRSU United States
  • Employees
  • ELVN N/A
  • PRSU N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • PRSU Business Services
  • Sector
  • ELVN Health Care
  • PRSU Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • PRSU Nasdaq
  • Market Cap
  • ELVN 1.1B
  • PRSU 959.1M
  • IPO Year
  • ELVN 2020
  • PRSU N/A
  • Fundamental
  • Price
  • ELVN $20.33
  • PRSU $34.83
  • Analyst Decision
  • ELVN Strong Buy
  • PRSU Strong Buy
  • Analyst Count
  • ELVN 5
  • PRSU 3
  • Target Price
  • ELVN $41.20
  • PRSU $31.33
  • AVG Volume (30 Days)
  • ELVN 573.6K
  • PRSU 185.0K
  • Earning Date
  • ELVN 11-07-2025
  • PRSU 11-05-2025
  • Dividend Yield
  • ELVN N/A
  • PRSU N/A
  • EPS Growth
  • ELVN N/A
  • PRSU 902.95
  • EPS
  • ELVN N/A
  • PRSU 10.75
  • Revenue
  • ELVN N/A
  • PRSU $441,143,000.00
  • Revenue This Year
  • ELVN N/A
  • PRSU $22.00
  • Revenue Next Year
  • ELVN $20.05
  • PRSU $8.35
  • P/E Ratio
  • ELVN N/A
  • PRSU $3.18
  • Revenue Growth
  • ELVN N/A
  • PRSU 4.63
  • 52 Week Low
  • ELVN $13.30
  • PRSU $26.66
  • 52 Week High
  • ELVN $29.38
  • PRSU $46.66
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 49.67
  • PRSU 46.47
  • Support Level
  • ELVN $16.80
  • PRSU $32.20
  • Resistance Level
  • ELVN $24.64
  • PRSU $38.30
  • Average True Range (ATR)
  • ELVN 1.45
  • PRSU 1.37
  • MACD
  • ELVN -0.23
  • PRSU -0.18
  • Stochastic Oscillator
  • ELVN 43.11
  • PRSU 37.41

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About PRSU Pursuit Attractions and Hospitality Inc. Common Stock

Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.

Share on Social Networks: